Global Exportin 1 Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Exportin 1 Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively.
Exportin 1 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Exportin 1 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Central Nervous System are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Exportin 1 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Exportin 1 key manufacturers include Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, Karyopharm Therapeutics Inc, Oita University Institute of Advanced Medicine Inc and Wigen Biomedicine Technology (Shanghai) Co Ltd, etc. Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd are top 3 players and held % sales share in total in 2022.
Exportin 1 can be divided into Chromosome Region Maintenance 1 Protein Homolog and XPO1, etc. Chromosome Region Maintenance 1 Protein Homolog is the mainstream product in the market, accounting for % sales share globally in 2022.
Exportin 1 is widely used in various fields, such as Oncology, Central Nervous System, Immunology and Genetic Disorders, etc. Oncology provides greatest supports to the Exportin 1 industry development. In 2022, global % sales of Exportin 1 went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Exportin 1 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Biogen Inc
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Segment by Type
Chromosome Region Maintenance 1 Protein Homolog
XPO1
Oncology
Central Nervous System
Immunology
Genetic Disorders
Infectious Disease
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Exportin 1 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Exportin 1, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Exportin 1 industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Exportin 1 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Exportin 1 introduction, etc. Exportin 1 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Exportin 1 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Exportin 1 report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Exportin 1 market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Central Nervous System are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Exportin 1 industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Exportin 1 key manufacturers include Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, Karyopharm Therapeutics Inc, Oita University Institute of Advanced Medicine Inc and Wigen Biomedicine Technology (Shanghai) Co Ltd, etc. Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd are top 3 players and held % sales share in total in 2022.
Exportin 1 can be divided into Chromosome Region Maintenance 1 Protein Homolog and XPO1, etc. Chromosome Region Maintenance 1 Protein Homolog is the mainstream product in the market, accounting for % sales share globally in 2022.
Exportin 1 is widely used in various fields, such as Oncology, Central Nervous System, Immunology and Genetic Disorders, etc. Oncology provides greatest supports to the Exportin 1 industry development. In 2022, global % sales of Exportin 1 went into Oncology filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Exportin 1 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Biogen Inc
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Segment by Type
Chromosome Region Maintenance 1 Protein Homolog
XPO1
Segment by Application
Oncology
Central Nervous System
Immunology
Genetic Disorders
Infectious Disease
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Exportin 1 market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Exportin 1, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Exportin 1 industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Exportin 1 in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Exportin 1 introduction, etc. Exportin 1 Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Exportin 1 market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices